ERBB3 and pancreatic neoplasm: Since ErbB3 is sometimes regarded as “undruggable’ due to its lack of phosho-activity,47 allosteric inhibitors were recently developed to prevent ErbB3 from dimer signaling.48 In another study, bi-specific antibody for IGF1R and ErbB3 was tested in preclinical models of pancreatic cancer.49 Further investigation is currently underway in our lab to investigate ErbB3’s role in LMD.